找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Rare Lymphomas; Martin Dreyling,Michael E. Williams Book 2014 Springer-Verlag Berlin Heidelberg 2014 Malignant Lymphoma.Molecular Pathogen

[复制链接]
楼主: Osteopenia
发表于 2025-3-30 08:57:49 | 显示全部楼层
Principles of the Pathology and Biology of Malignant Lymphomas 1988) and the working formulation for clinical usage (WF; Non-Hodgkin’s lymphoma pathologic classification project 1982). Both classification systems relied upon entirely different principles. The Kiel classification was based on the exact morphological description and (later) immunological identif
发表于 2025-3-30 14:24:10 | 显示全部楼层
发表于 2025-3-30 18:08:46 | 显示全部楼层
Signaling Pathways in Rare Lymphomasys are equally of importance and discussed in the context of with mantle cell lymphoma and Burkitt’s lymphoma. A striking example of how dysregulation of immune surveillance pathways interfaces with activation of oncogenic pathways is seen in the case of primary mediastinal B-cell lymphoma.
发表于 2025-3-30 23:16:05 | 显示全部楼层
发表于 2025-3-31 03:42:59 | 显示全部楼层
Anaplastic Large Cell Lymphomand Drug Administration for this disease. Crizotinib, which targets the ALK kinase and has shown promising results in preclinical and a limited clinical setting, is currently being evaluated in phase II clinical studies. Future directions will aim at changing current treatment strategies by incorpora
发表于 2025-3-31 05:39:40 | 显示全部楼层
发表于 2025-3-31 11:03:16 | 显示全部楼层
Primary Mediastinal Large B-Cell Lymphomaximab reduced these differences and R-CHOP is now the most widely used treatment, as it is for other types of DLBCL. The role of consolidation with local radiotherapy, which is often used to treat residual mediastinal masses, still remains unclear. Treatment with R-CHOP followed by radiation therapy
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-4 02:20
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表